Payment overview · 2025
General Payments
$699.73
29 reported records · 14 companies
Healthcare provider profile · identity verified
Olga Josephine Jacques
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · BRONX, NY · NPI 1508213992
Verified facts
What the public records show
CMS Open Payments records show Olga Josephine Jacques received $699.73 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.58 | 26.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.34 | 21.8% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.29 | 9.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.38 | 6.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.02 | 6.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.04 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.00 | 5.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.31 | 3.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $22.30 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.00 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.92 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.95 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.98 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.62 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.73 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.58 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $182.58 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $131.09 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.88 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $68.29 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.38 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 384 | 52 |
| Gabapentin | Gabapentin | 370 | 57 |
| Lisinopril | Lisinopril | 314 | 45 |
| Omeprazole | Omeprazole | 302 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 35 |
| Metformin Hcl | Metformin Hcl | 199 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 27 |
| Famotidine | Famotidine | 173 | 29 |
| Losartan Potassium | Losartan Potassium | 171 | 37 |
| Montelukast Sodium | Montelukast Sodium | 164 | 34 |
| Simvastatin | Simvastatin | 146 | 30 |
| Trazodone Hcl | Trazodone Hcl | 128 | 21 |
| Ammonium Lactate | Ammonium Lactate | 123 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 108 | 24 |
| Nifedipine Er | Nifedipine | 96 | 13 |
| Hydrocortisone | Hydrocortisone | 80 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 78 | 21 |
| Clotrimazole | Clotrimazole | 78 | suppressed |
| Jardiance | Empagliflozin | 75 | 14 |
| Furosemide | Furosemide | 73 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 15 |
| Glipizide | Glipizide | 72 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 12 |
| Ketoconazole | Ketoconazole | 67 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 62 | suppressed |
| Ozempic | Semaglutide | 60 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 13 |
| Carvedilol | Carvedilol | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Prednisone | Prednisone | 50 | 17 |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Lidocaine | Lidocaine | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Eliquis | Apixaban | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Baclofen | Baclofen | 43 | 20 |
| Meloxicam | Meloxicam | 43 | suppressed |
| Allopurinol | Allopurinol | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Piroxicam | Piroxicam | 41 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 37 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Fluocinonide | Fluocinonide | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Naproxen | Naproxen | 26 | 13 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Terconazole | Terconazole | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 14 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Nystop | Nystatin | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.73 · 29 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, Korlym, MOUNJARO, NEFFY, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VYEPTI, Veozah, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error